These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 35617132)

  • 1. Brinzolamide- and latanoprost-loaded nano lipid carrier prevents synergistic retinal damage in glaucoma.
    Chen L; Wu R
    Acta Biochim Pol; 2022 May; 69(2):423-428. PubMed ID: 35617132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fabrication and Characterization of Timolol Maleate and Brinzolamide Loaded Nanostructured Lipid Carrier System for Ocular Drug Delivery.
    Shrivastava N; Khan S; Baboota S; Ali J
    Curr Drug Deliv; 2018; 15(6):829-839. PubMed ID: 29189155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual Drug Loaded Lipid Nanocarrier Formulations for Topical Ocular Applications.
    Youssef AAA; Dudhipala N; Majumdar S
    Int J Nanomedicine; 2022; 17():2283-2299. PubMed ID: 35611213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brimonidine purite 0.1% versus brinzolamide 1% as adjunctive therapy to latanoprost in patients with glaucoma or ocular hypertension.
    Day DG; Hollander DA
    Curr Med Res Opin; 2008 May; 24(5):1435-42. PubMed ID: 18402717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brinzolamide loaded chitosan-pectin mucoadhesive nanocapsules for management of glaucoma: Formulation, characterization and pharmacodynamic study.
    Dubey V; Mohan P; Dangi JS; Kesavan K
    Int J Biol Macromol; 2020 Jun; 152():1224-1232. PubMed ID: 31751741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of Oral Lipid Based Nano-formulation of Dapagliflozin: Optimization, in vitro Characterization and ex vivo Intestinal Permeation Study.
    Zafar A
    J Oleo Sci; 2020; 69(11):1389-1401. PubMed ID: 33132278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Latanoprost-loaded phytantriol cubosomes for the treatment of glaucoma.
    Bessone CDV; Akhlaghi SP; Tártara LI; Quinteros DA; Loh W; Allemandi DA
    Eur J Pharm Sci; 2021 May; 160():105748. PubMed ID: 33567324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PLGA Nanoparticles as Subconjunctival Injection for Management of Glaucoma.
    Salama HA; Ghorab M; Mahmoud AA; Abdel Hady M
    AAPS PharmSciTech; 2017 Oct; 18(7):2517-2528. PubMed ID: 28224390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality by Design (QbD)-enabled development of aceclofenac loaded-nano structured lipid carriers (NLCs): An improved dermatokinetic profile for inflammatory disorder(s).
    Garg NK; Sharma G; Singh B; Nirbhavane P; Tyagi RK; Shukla R; Katare OP
    Int J Pharm; 2017 Jan; 517(1-2):413-431. PubMed ID: 27956192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brinzolamide loaded core-shell nanoparticles for enhanced coronial penetration in the treatment of glaucoma.
    Song J; Zhang Z
    J Appl Biomater Funct Mater; 2020; 18():2280800020942712. PubMed ID: 33151769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs?
    Das S; Ng WK; Tan RB
    Eur J Pharm Sci; 2012 Aug; 47(1):139-51. PubMed ID: 22664358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intraocular pressure lowering effect of brinzolamide 1.0% as adjunctive therapy to latanoprost 0.005% in patients with open angle glaucoma or ocular hypertension: an uncontrolled, open-label study.
    Shoji N; Ogata H; Suyama H; Ishikawa H; Suzuki H; Morita T; Kawai H; Nishimoto H; Nemoto T; Shimizu K
    Curr Med Res Opin; 2005 Apr; 21(4):503-8. PubMed ID: 15899098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of single glaucoma drug in combined timolol XE, latanoprost and brinzolamide therapy: a discontinuation study.
    Kobayashi H
    J Ocul Pharmacol Ther; 2012 Jun; 28(3):245-50. PubMed ID: 22283238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of concomitant use of latanoprost and brinzolamide on 24-hour variation of IOP in normal-tension glaucoma.
    Nakamoto K; Yasuda N
    J Glaucoma; 2007; 16(4):352-7. PubMed ID: 17570997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The intraocular pressure reducing effect of brinzolamide as adjunctive therapy to latanoprost.
    Li Yim JF; Montgomery DM
    Curr Med Res Opin; 2011 Aug; 27(8):1499-502. PubMed ID: 21651425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Ex Vivo Evaluation of Moxifloxacin Nanostructured Lipid Carrier Enriched In Situ Gel for Transcorneal Permeation on Goat Cornea.
    Gade S; Patel KK; Gupta C; Anjum MM; Deepika D; Agrawal AK; Singh S
    J Pharm Sci; 2019 Sep; 108(9):2905-2916. PubMed ID: 30978345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of ocular hypotensive effect and safety of brinzolamide and timolol added to latanoprost.
    Miura K; Ito K; Okawa C; Sugimoto K; Matsunaga K; Uji Y
    J Glaucoma; 2008; 17(3):233-7. PubMed ID: 18414111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cubogel as potential platform for glaucoma management.
    Sayed S; Abdel-Moteleb M; Amin MM; Khowessah OM
    Drug Deliv; 2021 Dec; 28(1):293-305. PubMed ID: 33509004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and dermatokinetic evaluation of Apremilast loaded nanostructured lipid carriers embedded gel for topical delivery: A potential approach for improved permeation and prolong skin deposition.
    Rapalli VK; Sharma S; Roy A; Singhvi G
    Colloids Surf B Biointerfaces; 2021 Oct; 206():111945. PubMed ID: 34216849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preparation and Characterization of Minoxidil Loaded Nanostructured Lipid Carriers.
    Wang W; Chen L; Huang X; Shao A
    AAPS PharmSciTech; 2017 Feb; 18(2):509-516. PubMed ID: 27120090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.